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Comparative output reviews
Some international benchmarks for evaluating
Australian health and medical research
Sam Garrett-Jones, Brian Wixted and Tim Turpin

Recent experience in Australia has seen the requirement by the federal Department of Finance
and Administration to conduct output pricing
reviews of government agencies including research organisations. Health and medical research, while generally regarded as an important
‘public good’, is now pressed by the same demands as other research fields to account for
public investments in terms of value of outcomes
and value for investment. This paper reports on
current trends towards international benchmarking of health and medical research performance.
Comparative data from overseas show unique
aspects of the Australian health and medical research funding system. The paper suggests possible future routes for carrying out health
research evaluation in Australia.

G

OVERNMENTS AROUND THE WORLD
are demanding greater accountability and
efficiency in the use of public monies for
research. This pressure to demonstrate outcomes and
effective use of funds has extended to research institutes and research councils. The health and medical
research and development (HMRD) community has
perhaps been more insulated than have, say, researchers in the social sciences. Governments appear
to have accepted incontestably that HMRD is a public good that is carried out to the highest professional
standards. There has been strong community support
for HMRD, and last but not least the medical establishment and researchers are very effective lobbyists.
Even so, HMRD is now operating in an environment
of greater public accountability which is affecting all
government-run or government-funded bodies.

Demand for research performance evaluation
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Through the 1990s there was growing pressure on
research funding agencies in most countries to report
on the return to society of publicly funded national
research investments and on the specific ‘results’ or
outcomes of that investment. In several countries,
this requirement has become enshrined in legislation
or administrative regulation. In the United States, the
1993 Government Performance and Results Act
(GPRA) requires strategic planning and performance
reporting for all government activities, including
research (Cozzens, 2000). Agencies such as the National Institutes of Health (NIH), which support fundamental research, now produce annual performance
plans that assess the institutes’ achievement of its
performance targets. Most of NIH’s performance
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goals are expressed objectively or quantitatively;
other goals are assessed through an ‘alternative
form’ such as descriptive criteria (OrdóñezMatamoros, 2003).
In Australia, federal government research agencies including the National Health and Medical Research Council (NHMRC) and CSIRO have since
1999 been subject to output pricing reviews by the
Department of Finance and Administration (DoFA).
These reviews examine the quantity, quality and
price of outputs produced in an attempt to assess
whether the government is getting good value for the
taxpayers’ funds. The process emphasises indicators
of agency outputs and outcomes.
• Outcomes in this context refer to longer-term impact or effect expected or intended in a particular
policy arena.
• Outputs are the immediate ‘deliverables’ — the
goods and services — produced by the agency
(Department of Finance and Administration,
2000).
As one moves from outputs to impacts, the results of
research activity are generally broader in their effect,
take longer to manifest themselves, are harder to
quantify and are less readily traceable to particular
research projects, funding programs or agencies.
This is the so-called ‘attribution factor’. While desired impacts may be seen, they have a plurality of
causes, the individual contribution of which is not
readily measurable. For example, while it may be
possible to demonstrate statistically a decline in
mortality or morbidity from a particular disease, it is
in most circumstances impossible to attribute this
with any confidence to a single cause, such as a
major NHMRC research program on the topic.
There is an inherent difficulty too, as US researcher
Paul David notes in respect of NIH, in requiring research agencies to consider ‘outcomes beyond the
span of control of the agencies which are being
asked to define their outcomes’ (Feller, 2002).
The Australian federal government framework
therefore sensibly recognises that research agencies
are valued as much for their standing capacity to
deliver research expertise as for their specific R&D
activities. In practice, the output pricing reviews of
research agencies have been largely qualitative in
nature (Commonwealth Scientific and Industrial Research Organisation, 2002).

International performance indicators
In the case of Australian HMRD, the results of performance evaluation have usually been used to justify greater investment and targeting of that
investment. As the primary funding body, the
NHMRC has been developing an outcomes evaluation model for several years. The Council explains
the rationale and objectives of the model thus:

156

Scrutiny of the returns from the investment in research is one of the consequences of the introduction of an outcome-based accrual budgeting
framework. The doubling of funding to the
NHMRC, and the recommendations arising
from the [Wills, 1998] Review, have encouraged
the NHMRC to re-examine the way it performs
its role as the peak funding body for Australian
health and medical research … A key underlying
theme of the Review calls for the NHMRC to
develop an evaluation framework to quantify the
outcomes of its investment in health and medical
research … The Research Outcome Evaluation
model … will form the basis of performance reporting for research funds managed by the
NHMRC for the conduct of health and medical
research. (NHMRC, 2001)
In the course of preparing its 2000–2003 Performance Report (NHMRC, 2003a), NHMRC therefore
sought to present data and case studies on the outputs, outcomes and impacts of its activities. The
Council asked the current authors to review and report upon performance indicators for HMRD that
were in common use overseas (Turpin, Wixted and
Garrett-Jones, 2003). The study had two main aims.
1. Benchmarking HMRD performance The first objective was to compare the performance of Australia’s HMRD with that of the HMRD sector in
other selected countries. However, this seemingly
simple question raises many issues about the appropriate comparisons to attempt and the availability of data to support these comparisons.
2. Benchmarking the use of performance indicators
The second objective, therefore, was aimed at
learning from international experience with
HMRD performance indicators, particularly with
regard to those used by medical research funding
organisations with similar functions to NHMRC.
Here the review examined the state of development of international indicator systems for assessing HMRD, and considered how Australia’s
HMRD system in general and the NHMRC in particular compared with international practice in
terms of the performance measurement frameworks being used.
The current paper briefly presents the main lessons
learned from this study in the broader context of
evaluation of HMRD. It explores, through examples,
the feasibility of international benchmarking of
HMRD and suggests how performance evaluation of
HMRD in Australia could be further developed.

Benchmarking of HMRD
‘Benchmarking’ can encompass many types of comparison of performance (Bureau of Industry Economics, 1996), but frequently implies a quantitative
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comparison. Benchmarking may be carried out for
the purpose of research evaluation, but has wider
application in policy analysis — e.g. for comparing
inputs or investments.
Research evaluation is concerned, literally, with
assessing the value of the work of a particular researcher or research group, department, institution,
agency or program. The focus is on the results, efficiency and effectiveness of the activity rather than
simply on its cost or use of resources. The aim of
research evaluation is to demonstrate to a particular
audience the appropriate performance of the activity
in question — Irwin Feller uses the term ‘multiple
publics’ in this context (Feller, 2002). This implies a
requirement to tailor the performance measure to
that audience and to use the sorts of evidence that
the audience finds convincing (Garrett-Jones, 2000).
A research council like NHMRC occupies a crucial
‘middle level’ (between government central agencies
like DoFA and the researchers) in assessing the performance of research. In developing and using performance indicators, it has to talk to both the
sponsor and the performer of research in language
that they understand, using measures of performance
that they find convincing. These measures may be
purely qualitative, and thus not amenable to
‘benchmarking’. In summary, research evaluation
and benchmarking are concepts that intersect but
which are not identical.
How do we apply them to evaluating HMRD?
First, let us look at the components the HMRD system and consider how elements of the system might
be used to ‘benchmark’ performance between countries. Figure 1 presents a stylised model of a research
system that might be applied to HMRD.
Resources (recurrent funding, capital stock, personnel, existing knowledge, etc.) are the inputs to
institutions or programs (research institutes, hospitals, universities, research councils) which ‘convert’
them into research outputs (publications, research
trained people, patents, etc). The outputs produce
beneficial health or other socio-economic outcomes
or impacts. The challenge for research evaluation is
to be able to tie the outcomes/impacts sufficiently to
the structures and institutions to be able to identify
the better performing institutions, programs or activities. These findings may influence the allocation
of resources through some kind of feedback
mechanism. In Australia, the federal education

department’s funding formula for universities which
takes account of various research ‘outputs’ is one
example.
One form of research benchmarking is the qualitative international comparison often made by highlevel peer review panels. Here, the performance of a
research discipline or institution may be ranked subjectively on the basis of its perceived international
standing in adequacy of resources, effectiveness of
structures and quality of outputs and outcomes. In
the USA, NIH and the Food and Drug Administration have been involved in international comparisons
by expert panels of the status of emerging areas such
as tissue engineering. In Australia, one can point to
the Australian Research Council’s reviews of grant
outcomes — for example, in molecular biology —
and the review of the Australian National University’s Institute of Advanced Studies (which includes
the John Curtin School of Medical Research) as instances of qualitative benchmarking (ARC, 1994;
1996).
Defining the HMRD system
The first issue is exactly how to define the scope of
HMRD, as represented by the central box in Figure
1. In practice it is quite difficult to come up with an
acceptable definition for the ‘structures’ box in Figure 1. The OECD uses the term ‘non-market R&D’
to cover the public sector and non-profit private
(PNP) foundations, but to exclude commercial
HMRD performers. Alternatively, comparisons may
be based upon government budget data (again as the
OECD does) or funding, or on expenditures by particular agencies.
Table 1 shows the broad picture of HMRD expenditure and funding in Australia. From the table it
is apparent that any analysis that considered only the
Commonwealth government budget or the ‘nonmarket’ sector, for example, would only partially
cover the HMRD sector. An alternative approach is
to try and compare specific sub-sectors or agencies
— for example, health research councils in different
countries, or various schemes for supporting collaborative research.
In summary, the first problem in benchmarking is
that structures, institutions and organisations are
specific to the sector or country in question. Their
performance can be measured in many cases, but

Feedback

Structures
Resources

Inputs

(organizations,
programs, activities,

Outputs

Outcomes
Impacts

processes)

Figure 1. A stylised model of a research system for evaluation purposes,
(after Arnold and Guy, 1998)
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Table 1. Australian HMRD expenditure by sector of funding and sector of performance, 2000 (A$ mill.)

Sector providing funds

Sector carrying out R&D
Government
research institutes

Commonwealth govt research
agencies’ own funds
State govt research agencies’
own funds
Universities’ own funding
(general university funds)
Business enterprises’ own
funds
Other Australian own funds
Commonwealth govt funding
Other Commonwealth govt
funding for universities
Other schemes’ funding for
universities
State govt funding
Universities’ funding
Business funding
Joint business/ govt funding
Other Australian (incl. PNP)
funding
Overseas funding
Total HMRD

Universities

Other Australian
(incl. PNP)

Business
enterprises
(pharmaceuticals
only)

Total HMRD

21.3

21.3

51.9

51.9
360.4

360.4
198.6

27.7

130.5

60.6
44.8

39.6
18.9
4.0
27.6
0.2

6.8
27.8
37.9

198.6
60.6
203.1
39.6

20.6
2.1
14.2
0.7

6.8
67.4
6.1
79.7
0.9
88.3
45.3

25.5
5.6

38.7
26.1

24.2
13.6

182.7

667.7

180.8

198.6

1,229.7

Source: Turpin, Wixted and Garrett-Jones, 2003

these measurements cannot be directly compared
with the situation in other sectors or countries.
Classifying the purpose of HMRD
One way to overcome the constraint imposed by
specific local structures and institutions is to adopt a
functional classification for R&D carried out in all
sectors (i.e. businesses, public institutes, universities, hospitals). This would allow, as an example, a
comparison of R&D effort on reproductive medicine
between countries. The federal statistics agency in
Australia classifies all R&D by socio-economic
objective (SEO). The SEO subdivision for ‘health’
covers ‘R&D directed towards human health, including the understanding and treatment of clinical diseases and conditions and the provision of public
health and associated support services’ (Australian
Bureau of Statistics, 1998). The subdivision has

The performance of structures,
institutions and organisations can be
measured in many cases, but these
measurements cannot be directly
compared with the situation in other
sectors or countries
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three groups: clinical (organs, diseases and abnormal
conditions), public health, and health and support
services. Comprising these groups are 49 classes,
some of which refer to specific diseases or medical
specialisms (e.g. endocrine organs and diseases
(incl. diabetes); health related to ageing; diagnostic
methods). R&D related to human pharmaceutical
products and medical instrumentation are covered
separately within the manufacturing subdivision of
the classification.
Australia is fortunate in the degree of detail provided in its functional (SEO) classification of R&D.
Regrettably, such comprehensive SEO classifications are not widely used. As Alison Young (2001)
comments:
National specificities are particularly evident in
the arrangements for non-market health R&D.
National experts can mix and match institutional and functional data to reach a data set
that they feel gives a reasonable picture of the
level and structure of the R&D activities of
their own National Health Science and Innovation Systems. Only Australia took a purely
functional approach, providing series based on
socio-economic objective and on field of S&T.
Austria, Denmark, and to some extent Israel,
also collected some project-level data in the
non-market sector. Such detail was not available for Canada, France, the United Kingdom
and the United States, which used semiinstitutional approaches. R&D in the medical
sciences was included for the university sector

Research Evaluation December 2004
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(incl. university hospitals). France and the
United States also included some (United
States) or all (France) other life sciences. [Emphasis added]
The second problem, then, is the lack of an internationally accepted, detailed functional classification
of R&D. This seriously limits the scope for international benchmarking of HMRD although, for the
academic sector and for research publications, use of
classification by field of research is an alternative
approach. Analyses of the published outputs of Australian HMRD (Butler, 2003) use three separate
‘field’ classifications, for example.1 This situation is
likely to improve. Through the Health Research Systems project the World Health Organisation (WHO)
has supported work aimed at describing and measuring health research systems in developing countries
(Alano and Almario, 2000). The NHMRC is participating in the WHO project.
Measuring inputs, outputs and outcomes
Inputs and outputs can be counted more readily than
outcomes and impacts. Research inputs (personnel
and funding) are usually quantifiable. For most inputs the indicators are internationally standardised;
for example, through adherence to the OECD’s
‘Frascati family’ of guidelines and manuals. International standards or practices also exist for the measurement of many research outputs (publications,
qualified people, patents), through firms like the Institute for Scientific Information (ISI) or agencies
like national or regional patent offices. Outcomes
and impacts, on the other hand, often cannot be sensibly quantified and their assessment rests on qualitative criteria. A notable exception is the widespread
use of impact measures of HMRD publications
through analysis of the frequency of citations to papers in the international literature. International
comparison is facilitated by ISI’s databases and
common classifications of research fields. It can be
argued that bibliometrics provides evidence of the
scientific impact of research rather than of its contribution to health outcomes. Given the time lag and

the often indirect contribution of HMRD, attributing
particular health outcomes to particular research
programs is likely to be infeasible in most cases.
Table 2 takes a real-life example and describes
some of the indicators used to assess the performance of the Australian Cooperative Research Centres
(CRCs). The program provides substantial funding
for health and medical CRCs (Garrett-Jones and
Turpin, 2002). These indicators are grouped under
the headings of inputs, structures, outputs and outcomes. As can be seen, the outcomes indicators rely
heavily on qualitative assessments or case studies,
although separate bibliometric analyses have looked
at the relative impact of publications from the health
and medical CRCs (Butler, 2003). The outcomes
performance measures used by NHMRC also rely on
a mix of qualitative information (such as ‘success
stories’) and bibliometrics (NHMRC, 2002; 2003a).
The NHMRC has made extensive use of bibliometric analyses in benchmarking Australian biomedical
research and to determine the scientific impact of the
work that the council itself funds (Butler, 2003; Butler and Biglia, 2001; Butler et al, 1998). Bibliometric evidence was used very effectively in the Wills
Review of health research in Australia (Wills, 1999).
The third problem, then, is the difficulty of comparing research outcomes between agencies, sectors
or countries. Benchmarking of HMRD is therefore
fraught with more uncertainty than are comparisons
of ‘hard’ health infrastructure (e.g. hospital beds per
1,000 population in different countries). Because we
can measure them readily, it is more feasible to
benchmark R&D inputs and outputs than it is to
benchmark outcomes. But there remain substantial
difficulties even in comparing the resources available to health research in different countries.

International approaches
Faced with these difficulties, what are other countries
doing in HMRD evaluation methodology and practice? A selection of HMRD funding and research
agencies from various countries (Table 3) is used to
illustrate some differences and commonalities in the

Table 2. Some performance indicators used for health and medical cooperative research centres in Australia

Inputs
Research staff
Technical and support staff
Research student enrolments
Resources (staff, students,
funding) by SEO and by subprogram
Cost per staff member

Structures
Industry participation (no. of
firms, funds)
No. of students co-supervised by
industry
No. of participants in CRC (core/
supporting/other)
Level and growth in funds and
contributions from participants
Proportion of levered funds to
CRC program funds
No. of strategic international
alliances

Research Evaluation December 2004

Outputs
Contracted research and
consulting (cases and income)
Technology agreements, spin
off companies
Patents held and filed in
Australia and overseas
Technology transfer and
professional training courses
held (no. and income)
Research student completions

Outcomes
Qualitative statement of
achievements and outcomes
Defined successful outcomes in
research, teaching and
commercialisation
Return on investment case studies
Qualitative account of most
successful research outcomes
No. of students taking up
employment with industry
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current use and development of performance indicators. It appears that international HMRD agencies
are under the same pressures as NHMRC to report
on the outcomes of the research and training activities they carry out or fund. Thus, many are implementing formal reporting of research ‘results’,
usually through both statistical and qualitative
measures of performance. Agencies faced with this
task have adopted closely similar hierarchical approaches that
• identify the top level objectives that are to be
achieved;
• show how the objectives of the research groups,
centres, projects or institutions relate to the top
level objectives; and
• specify available or potential indicators that can
measure performance against both top level and
research group objectives.
About half of the agencies reviewed in Table 3 either
publish such performance indicators, or are developing or planning to develop them.
The review of the international data revealed several common features in the evaluation systems used
by HMRD agencies.
• Because of the relatively recent history of HMRD
performance evaluation there is less international
standardisation than in other sectors of research.
However, the study found no fundamental difference between systems that aim to measure the per-

formance of HMRD and those for assessing
research aimed at other socio-economic objectives.
• HMRD evaluation systems commonly take a hierarchical approach, linking top level (government
or agency) objectives to outcomes that are valued
at the research level, and to specific indicators
that can inform the assessment of these objectives
and outcomes.
• The better performance measures systems
integrate qualitative and quantitative measures of
performance and internal and external assessment. A framework that relies primarily on external qualitative review is expensive and difficult to
implement and the results are likely to be incomparable with those obtained by other agencies.
Systems that rely on readily available, internally
generated statistical data are easier to define and
implement, but risk overlooking the assessment of
quality and relevance that can be provided by external review.
• The long-term social impacts and health impacts
of HMRD are commonly assessed through qualitative studies involving the potential beneficiaries
rather than through standardised statistical indicators.

Benchmarking Australian HMRD
While many agencies have or are developing sophisticated performance measures, the issues outlined
earlier mean that there is relatively sparse data avail-

Table 3. Use of performance indicators by HMRD agencies internationally

Country

Health and medical R&D agency

Status of performance indicators

Canada

Canadian Institutes of Health Research (CIHR),
Reasonable information available. Performance
formerly the Medical Research Council (MRC) of
indicators being further developed
Canada
France
Institut national de la sante et de la recherché medicale Limited information available on performance
(INSERM)
Germany
Bundesministerium für Bildung und Forschung (BMBF) Good information on the structure of the health and
– the Federal Ministry of Education and Research
medical R&D system but availability of performance
indicators limited
The Netherlands
Netherlands Organisation for Health R&D (Zon-Mw),
Does not collect information on publications, patents or
incorporating the former Zorg-Onderzoek Nederland
commercialisation activities
(ZON) – Health R&D Council and Medische
Wetenschappen van NWO (MW-NOW) – Medical
Sciences-Netherlands Organisation for Scientific
Research
New Zealand
Health Research Council (HRC)
Annual ‘Progress and Achievements Report’ gives
qualitative and quantitative performance indicators.
Funding a bibliometrics study of publications arising
from HRC grants
Singapore
National Medical Research Council (NMRC), Ministry
Little relevant information found. Current output reported
of Health
does not allow for useful comparisons with Australia
South Africa
Medical Research Council (MRC)
Designing a performance indicators system
Switzerland
Swiss National Science Foundation (SNSF)
Financial (research expenditure information only).
Annual report does not report on performance
indicators and other publications do not appear to
carry such material
United Kingdom
Medical Research Council (MRC)
Readily accessible information on performance.
Performance indicators being further developed
United States of America National Institutes of Health (NIH)
Several sources of information including annual
performance plans and reports. Performance
indicators being further developed.
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Table 4. HMRD ‘budget’ funding as a proportion of national
health care expenditure and per head

Country

USA
Singapore
New Zealand
UK
Canada
France
Australia
Netherlands
Germany (Est. b)
South Africa
Switzerland
Germany (Est. a)

but as health care expenditure is also budget-driven,
the comparison may be appropriate. Some estimation is required, as in the alternative figures for
Germany. HMRD spending per capita is given for
comparison.
The analysis reveals strong similarities between
the countries (except the USA), with most spending
between 0.3% and 0.55% of their health care budget
on HMRD. Australia falls within the mid range of
the countries examined.

HMRD as % of health Institutional HMRD
care expenditure
funding per capita
(US$)
1.50
1.24
0.54
0.53
0.41
0.39
0.38
0.35
0.31
0.31
0.30
0.20

64.06
8.14
6.40
8.92
8.02
8.82
6.89
7.53
8.43
0.70
11.33
5.50

Functional priorities in HMRD
Despite the problems of incompatible functional
classifications of HMRD, the study attempted a
breakdown by health objective for the major research funding agencies in seven of the countries.
Table 5 gives an (incomplete) indication of the research priorities adopted by HMRD agencies in
these countries. Agencies in several countries spent
a similar proportion of their funding on AIDS research, and the same pattern was true for the categories of mental health and infection/immunity. The
table gives an idea of the value of benchmarking
using a detailed classification of the objective of
HMRD. Another way of examining the relative national priorities in HMRD, at least for the more fundamental research, is through a country’s share of
world publications in a field (see Table 6).

Source: Turpin, Wixted and Garrett-Jones, 2003

available for international benchmarking of HMRD.
Some examples of feasible comparisons are given
below. Each benchmark comprises a set of defined
indicators (based on inputs, outputs and less commonly outcomes). As noted, the available comparisons are predominantly of research inputs and
outputs, rather than outcomes. Comparisons are
found within the following ‘domains’ or levels of
evaluation: international, national, program or
agency benchmarks.

HMRD priorities in relation to burden of disease
Intensity of HMRD spending
The federal and state governments in Australia have
nominated seven national health priority areas based
upon considerations of burden of disease and potential for improved health outcomes. These are:
asthma, cancer control, cardiovascular health, diabetes mellitus, injury prevention and control, mental
health, and arthritis and musculoskeletal conditions

Table 4 compares the intensity of national HMRD as
a proportion of the national expenditure on health
care in Australia and 10 other countries. The data are
based on government budget expenditure for the
main public HMRD agencies. As noted earlier,
‘budget’ data are incomplete as a national picture,

Table 5. Agency funding by health area (percentage of identified R&D expenditure)

Health objective

Cancer, cancer prevention and related disorders
Cardiovascular health and diseases
Endocrine diseases and diabetes
Injury
Mental health and neurosciences
Respiratory diseases
Bone, joint and muscle diseases
Human genetics and inherited disorders
Infection and immunity
Liver, kidney and gastro-intestinal health and
diseases
Other health issues, diseases and conditions
Reproductive health
Social and environmental health issues
Population groups and health
Health sector/system management
AIDS research

Australia
2002

14.9
11.0
4.2
3.2
16.0
4.9
4.0
3.8
16.4
4.9
10.8
4.3
1.6

Germany
2002

NZ
2001

Canada
2001

UK
2001–02

5.4
3.7
13.2
14.2
13.4

1.2
0.8
3.9

USA
2002

Singapore
2000

21.0
8.7
3.6
15.3

16.7

25.3

17.1
16.7

6.0
6.2

14.0
10.7

10.7

10.7

Source: Turpin, Wixted and Garrett-Jones, 2003
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Another way of examining the relative
national priorities in HMRD, at least
for the more fundamental research, is
through a country’s share of world
publications in a field

(Mathers et al, 1999). In 2003, over 60% of
NHMRC funding was dedicated to research in these
priority areas (NHMRC, 2003a).
Research priorities within NHMRC have reflected
national health priorities and, more recently, the national research priorities (NRPs). ‘Promoting and
maintaining good health’ is one of four NRPs announced in 2002. Four specific goals — infant and
child health, ageing, preventive healthcare, and the
social and economic aspects of health — are identified as contributing to this priority. Research into
biotechnology and genomics is included under other
priority areas.
In response to the NRP initiative, NHMRC established strategic research networks (SRNs) in each of
three health-related areas: ‘Healthy Start to Life’,
‘Ageing Well, Ageing Productively’ and ‘Preventive
Healthcare’. The Council has borrowed the concept
of ‘consensus conferences’ from the US NIH with
a view to developing further SRNs (NHMRC,
2003b). The Council has also identified priority areas,

most notably Aboriginal and Torres Strait Islander
health.
Unfortunately, the ability to benchmark these investments is severely limited by the lack of a common international functional or ‘disease-based’
classification for HMRD expenditures.
HMRD outputs and impacts
Ideally, the ‘priorities’ data in Table 5 (which measures funding inputs) should be compared with the
performance of each field as measured by outputs,
such as publications or patents, or impacts such as
citations to Australian HMRD papers. Table 7 shows
Australia’s ranking in published scientific papers in
three HMRD sub-fields (clinical medicine, biomedical research, and health R&D) as defined by the US
NSF. The countries chosen for comparison were the
principal European OECD countries with Canada,
the USA and New Zealand. Data are expressed as
number of publications per head of population. Australia ranks in the middle of the pack for both clinical medicine and biomedical research. However, for
its population size Australia publishes more research
in the sub-field of ‘health’. The four Scandinavian
countries are prominent towards the top of the list
for both clinical and biomedical research.
Data on publications can also be used as a measure
of research impact. Using journals listed by the ISI for
the period 1996–2000, Butler (2003) has investigated
the citations attracted by published Australian biomedical papers against two benchmarks. The first
compares the actual rate of citation to Australian

Table 6. Australian and world citation rates for biomedical papers, 1996–2000

Research fielda

Biological Sciences
Biochemistry and cell
biology
Genetics
Microbiology
Biotechnology
Medical and health
sciences
Immunology
Pharmacology and
pharmaceutical science
Medical physiology
Neurosciences
Clinical sciences
Public health and health
servicesc
Medicine – general and
internal
Multidisciplinary
science
Source:
Notes:
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Australia –
no. of
papers

Australia – Australia – Australia –
World –
Australia –
no. of
citation rate citation rate citation rate
actual
citations –
– actual
– expected
citations/
actual
expected

Australia –
actual
citations/
worldb

Australia –
share of
world
papers

6,790
2,100
1,668
2,147

50,037
15,255
8,542
10,058

7.4
7.3
5.1
4.7

7.3
7.4
5.0
4.6

8.3
8.2
5.0
4.6

1.01
0.98
1.02
1.02

0.89
0.89
1.02
1.03

2.4%
3.5%
2.8%
2.6%

30,663
2,696

143,234
20,806

4.7
7.7

4.5
7.3

4.8
6.8

1.04
1.06

0.98
1.13

2.8%
2.9%

2,654
2,253
3,048
19,547

10,028
7,731
16,553
93,902

3.8
3.4
5.4
4.8

4.1
3.6
5.9
4.5

4.0
3.9
6.3
4.7

0.92
0.95
0.93
1.06

0.95
0.89
0.87
1.03

2.1%
4.1%
2.4%
2.7%

3,412

10,235

3.0

3.0

3.3

1.00

0.90

3.7%

2,215

12,754

5.8

5.2

5.7

1.12

1.01

3.1%

1,389

16,748

12.1

13.3

11.4

0.91

1.06

1.8%

Data from Butler (2003)
a. Fields omitted because of low publication counts are: clinical chemistry; dentistry; nursing; human movement and sports
science; and other medical and health sciences.
b. This measure is equivalent to the relative citation impact (RCI) indicator described by Butler et al, 1998.
c. ISI captures only about 25% of Australian articles in Public Health and health services. In other fields, ISI captures more than
80% of articles.
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Table 7. Ranked comparison of published papers in HMRD fields (papers/million pop. 1999)

Clinical medicine
Sweden
Switzerland
Finland
Denmark
Netherlands
UK
Norway
Austria
Australia
USA
Canada
New Zealand
Belgium
Germany
France

Biomedical R&D
383.5
343.6
328.1
287.3
253.0
226.9
202.0
197.8
197.1
192.9
192.4
162.7
160.5
134.5
126.0

Switzerland
Sweden
Denmark
Finland
USA
Netherlands
Canada
UK
Australia
Belgium
Norway
France
Germany
Austria
New Zealand

162.5
154.2
139.0
113.0
101.8
101.0
100.7
96.1
89.3
76.2
72.8
70.1
67.7
62.4
51.7

Health R&D
Australia
UK
Finland
Canada
Sweden
USA
Netherlands
New Zealand
Norway
Denmark
Switzerland
Belgium
Germany
Austria
France

All fields of research
12.6
11.3
10.1
9.7
9.4
9.0
7.3
6.9
5.8
3.9
2.9
1.4
0.9
0.9
0.5

Switzerland
Sweden
Finland
Denmark
UK
Australia
Netherlands
Canada
New Zealand
USA
Norway
Belgium
France
Germany
Austria

979
940
779
776
667
661
660
646
623
599
582
479
455
454
442

Sources: Turpin, Wixted and Garrett-Jones, 2000; after National Science Foundation, 2002; population data from OECD, 2002.

papers to the average citation rate for papers in the
journals in which they are published (the ‘expected’
citation rate). The second, the relative citation impact,
or RCI (Butler et al, 1998), makes comparison with
the world average for citations to biomedical papers
published in all ISI-listed biomedical journals. These
two benchmarks may differ if, for example, the Australian papers are published in ‘lower impact’ journals, i.e. those with a lower average citation rate per
paper, than is normal for the field.
Table 7 shows the results of this comparison
for selected main fields of HMRD. Butler (2003)
demonstrates that, for most sub-fields in Australia,
the actual citation rate per paper approaches or exceeds the ‘expected’ citation rate. The sub-fields of
general medicine, immunology and clinical sciences
show the highest citation impact. Using the RCI, the
fields showing an impact greater than the world average are immunology, clinical sciences, biotechnology and microbiology. Sub-fields like neuroscience
and medical physiology return a relatively weaker
performance against both indicators.
Overall, Butler’s data (Table 6) suggest that the
average citation rate of Australian biomedical papers
is on a par with the international benchmarks, but
there is a slight tendency for papers to appear in
journals with a citation ‘impact’ that is lower than
the world average. This suggests that fundamental
HMRD is performing notably well by international

Perhaps Australia’s HMRD system
overall is skewed towards applied
research, at least by comparison with
the publications emanating from the
major European and North American
research centres
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benchmarks, but perhaps that Australia’s HMRD
system overall is skewed towards applied research
(which tends to be less highly cited), at least by
comparison with the publications emanating from
the major European and North American research
centres which largely determine the ‘world’ average.
While the data on publications and citations reveal that Australian HMRD has been performing
strongly, the same does not appear true in patenting.
A recent study of patenting in health-related fields
(Lichtenberg and Virabhak, 2002) investigated patenting in the field ‘Medical or Veterinary Science;
Hygiene’ — meaning pharmaceuticals. The authors
used the OECD ‘Triadic Patent Families’ database,
which consolidates raw patent data from the European, Japanese and US Patent Offices. Among the
benchmark OECD countries only New Zealand
ranked lower than Australia in terms of its share of
world health patents (Table 8). Furthermore, time
series data show that Australia’s performance in patenting, as a proportion of world activity, is declining
(Lichtenberg and Virabhak, 2002).
HMRD outputs benchmarked
One of the concerns that prompted the current study
was whether research funded by NHMRC was
achieving appropriate outputs and outcomes by comparison with R&D funded by other research councils.
Butler (2003) clearly demonstrates that research supported by the NHMRC attracted citation rates that
were greater than the Australian average and, in all
but two sub-fields, were also above the world average
(i.e. RCI > 1.0). The rate of both actual and expected
citations was substantially higher for the more fundamental research supported by the NHMRC or carried out in specialist research institutes and
cooperative research centres than for the biomedical
publications from other research groups in government laboratories, hospitals or universities. As there
are few cases where HMRD activities can be compared directly with similar international activities
in other fields of research, Table 9 examines the
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Table 8: Health patents by OECD country of inventor, all
years (1988–1995)

Country

USA
EU
Japan
Germany
France
UK
Sweden
Switzerland
Italy
Canada
Netherlands
Denmark
Belgium
Australia
Austria
Spain
Finland
Norway
Korea
Hungary
Ireland
New Zealand
OECD

No. of health patents
(weighted)
22,409.4
10,810.1
4,292.2
3,030.5
2,301.1
2,225.5
1,024.3
759.5
716.6
684.2
448.2
311.6
243.0
224.3
212.5
124.2
121.6
97.5
80.3
58.3
57.0
31.4
39,558.6

% of world health
patents
55.8%
26.9%
10.7%
7.5%
5.7%
5.5%
2.6%
1.9%
1.8%
1.7%
1.1%
0.8%
0.6%
0.6%
0.5%
0.3%
0.3%
0.2%
0.2%
0.2%
0.1%
0.1%
98.4%

Source: Lichtenberg and Virabhak, 2002

contribution of HMRD within the Australian Cooperative Research Centres Program. Health and medical research accounts for around 11% of the
researchers within the CRC program. However,
medical CRCs contribute a higher proportion of CRC
outputs in several areas, notably in the numbers of
patents and the value of technology agreements.
In summary, the range of ‘benchmarks’ of Australia’s HMRD performance is limited, and several involve ‘best estimates’ of other countries’
performance. One should be rather cautious about
interpretation, especially as no measures of the quality or international recognition of Australian HMRD
(beyond those of citation impact) are presented.
Table 9. Outputs from medical Cooperative Research
Centres in Australia

CRC program performance
measure

Contribution of medical
CRCs to the program total
(1991–92 to 2000–01
except where indicated)

Researchers (full-time equivalent)
Papers accepted for publication
Journal articles published, 2000–01
Patents maintained in Australia
Patents filed in Australia
Patents maintained overseas,
2000–01
Patents filed overseas, 2000–01
No. of R&D contracts and
consultancies
Value of R&D contracts and
consultancies (at 2001 prices)
No. of technology agreements
Value of technology agreements
Source: Garrett-Jones and Turpin, 2002
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10.6%
11.0%
12.3%
38.0%
31.9%
21.4%
25.0%
3.7%
12.6%
11.8%
27.9%

However, on the data available, Australia’s HMRD
community seems to perform well, typically being
ranked with the medium-sized European countries,
Canada and New Zealand. There is little to separate
these countries in terms of public resources for
HMRD and they have rather similar research priorities. Australia ranks close to the UK and USA in
published papers (per capita) in clinical medicine
and biomedical R&D and ahead of both in health
R&D. Australia also performs very well in terms of
the impact of published HMRD. Where Australia
appears less competitive is in the area of potential
commercial outcomes of research. The number of
Australian health patents is around half that of the
Netherlands, for example — a country with a similar
population — and our output appears to be declining. This may reflect the performance of the business sector, which is not well captured in the
benchmarks presented.

Conclusions and future work
The current study revealed something of a paradox
about benchmarking the performance of Australian
HMRD. On the one hand, even though performance
evaluation of HMRD is a relatively new area, many
international HMRD agencies have developed formal frameworks for reporting research ‘results’, or
are doing so. On the other hand, there is rather limited scope for benchmarking of performance between countries. The prevalence of quantitative
reporting on the basis of local organisational structures and categories makes even comparison of
HMRD inputs difficult.
It is important to stress that, while there is of
course potential for Australia to learn from the experience of other countries and other fields of research of performance evaluation — such as recent
critiques of the influence of the US GPRA (Feller,
2002) — the lack of comparability is not because we
are dragging our heels. Through NHMRC, Australia
is keeping abreast of international best practice in
HMRD performance evaluation. Further, with the
comprehensive Australian Standard Research Classifications (ASRC) Australian statisticians are leaders
in measuring detailed R&D objectives which help
greatly in benchmarking R&D outcomes across the
public and business sectors.
What, then, is required to improve the evaluation
and international benchmarking of Australian
HMRD? In conclusion, we put forward some proposals, pose some questions, and suggest possible
avenues for future work.
A more structured approach
Without constructing a Byzantine evaluation framework, first consideration must be given to the objective of the benchmarking and the appropriate
indicators to include. This reiterates our earlier
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comment on tailoring the evidence to the audience,
in order to satisfy the ‘multiple publics’ for research
evaluation. Both statistical indicators and measures
of quality have a role in this process. In reviewing
international practice the study observed four levels
or ‘domains’ of benchmarking, as follows.
• International benchmarking — data that attempt
to reflect the performance at the national level
(e.g. research funding, publications, citation
analyses and commercialisation indicators, such
as patents). Because of government reporting requirements, the emphasis to date has been on publicly funded R&D. There is a need to incorporate
the HMRD activities of business and the nongovernment sector to give a full national picture.
• National benchmarking — benchmarking different national agencies (e.g. NHMRC and the CRC
program) serves to assess their contribution toward national priorities. Here, some commonality
of performance indicators between agencies
would assist benchmarking, provided they were
consistent with agencies’ goals.
• Agency/institute benchmarking — performance
measures in this category would include areas
such as the administrative cost and efficiency of
administering programs, as well as some aggregate of the program benchmarks described below.
• Program benchmarking — NIH’s program level
benchmarks using descriptive performance assessments and independent expert reviews provides a good example of this approach. Agencies
such as NHMRC might record, on a regular basis,
systematic information on qualitative outcomes.
For example, grant recipients could be asked, on
an annual basis, to identify and describe: (a) their
most significant research breakthrough and (b)
their most significant health/medical outcome.
Each of these ‘domains’ contributes to an appropriately balanced portfolio of performance measures for
a HMRD agency.
Common classifications?
As we have noted, one significant impediment to
benchmarking is a lack of standardisation in the
classifications used internationally for HMRD. This
makes it hard to compare rigorously even inputs to
HMRD between countries. Various different classifications are used for university and business research, and for inputs and outputs. Often, data are
expressed in terms of a hybrid classification of organisational units, health specialisms and specific
diseases or other health problems. The latter are
more likely to be of interest in assessing the contribution of HMRD to improved health outcomes and
reducing the quantified burden of particular diseases
(Mathers et al, 1999). But, when it comes to the
benchmarking the outcomes of HMRD, comparable
international data are almost non-existent.
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International benchmarking of HMRD performance would certainly be simpler and more robust if a
common international and cross-sectoral (public/
academic/private) detailed classification of HMRD
objectives (SEO), like the Australian one, were to be
implemented. This is, however, unlikely to come
about quickly and, even if it did, would take us only
part of the way towards comparing HMRD outcomes. The goal of these classifications is to specify
the intended beneficiary of the research, and the
categories used are not necessarily those which
would be most helpful for tracking outcomes.
The more fundamental issue remains that of
assessing the impact or outcomes of HMRD in terms
which make sense to the researchers and stakeholders involved, and expressing these in ways
which bear international comparison. Performance
evaluation will always require a mix of statistical
indicators and more qualitative, descriptive information on and expert assessment of research accomplishments. It is very hard to ‘benchmark’ the latter,
although it can sometimes be put in semiquantitative terms (e.g. proportion of research objectives met or not met). Any assessment of the outcomes of HMRD is a two-stage process. It involves
identifying the desired health outcomes, and then
endeavouring to assess the contribution of HMRD to
achieving those outcomes. In other words, benchmarking of HMRD performance is informed by, and
in turn informs, the development of health outcomes
goals and indicators. It must involve both the health
and medical research community (who are the best
judges of research quality) and the users and practitioners (who are best qualified to assess the impact
and application of the research findings).
Perhaps, when proposing international benchmarks for HMRD outcomes, a more targeted, collaborative approach is therefore required. Clearly,
there are many specific health issues (areas like
HIV/AIDS or mental health) where improved outcomes are of vital concern to many countries. International cooperation to define these specific areas
and to track the contribution of HMRD to improved
outcomes is one way forward which is likely to be
acceptable to many countries. Success in this approach might prompt a closer alignment of the more
general R&D classifications with categories used by
the health outcomes evaluation community.
In conclusion, we would argue that further effort
in assessing the outcomes and impacts of HMRD in
Australia should be more closely connected with
work that aims to develop health outcome indicators
and measures of the health-related quality of life.
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Notes
1. These are the ISI subject category for journals, the ABS research field, courses and disciplines (RFCD) categories, and
an internal NHMRC classification which more closely reflects
clinical specialisms.
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